RESEARCH PROGRAM
The Problem
High-grade serous ovarian cancer (HGSOC) is the most malignant and most frequently encountered type of ovarian cancer. Patients are typically diagnosed at an advanced stage, with large intratumoral heterogeneity and thus exhibit only transient treatment responses.
The standard of care for HGSOC patients consists of debulking surgery combined with platinum-based chemotherapy. Although initially responding to chemotherapy, eventually most patients will develop recurrent disease and resistance to this treatment. In the past 25 years, the overall survival of patients with ovarian cancer has not improved significantly.
Cellular heterogeneity, both genetic and non-genetic, facilitates tumor evolution upon treatment and the subsequent development of resistance. Apart from mutations in DNA repair pathways, HGSOC tumors lack shared targetable genomic drivers and instead, each patient’s tumors present a unique and highly variable combination of copy number aberrations and structural variants from the ancestral dominant cancer clone. This interpatient heterogeneity highly complicates classification and targeting of intratumoral chemoresistance-associated heterogeneity across patients.
Thus, innovative approaches are required to find markers defining the chemoresistant subpopulations, and precision drugs that kill each one of them.
A novel personalized treatment approach
The overall aim of the project is to find markers for HGSOC patient stratification and precision drugs for targeting the cellular subpopulations that do not respond to current treatments.